뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 2 mg/ml;  ; timolol maleate 6.8 mg/ml equivalent to timolol base 5 mg/ml;   - eye drops, solution - 2mg/ml, 5mg/ml - active: brimonidine tartrate 2 mg/ml   timolol maleate 6.8 mg/ml equivalent to timolol base 5 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate hydrochloric acid monobasic sodium phosphate monohydrate purified water sodium hydroxide - combigan® eye drops are indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension not adequately responding to monotherapy.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 2 mg/ml;   - eye drops, solution - 0.2 % - active: brimonidine tartrate 2 mg/ml   excipient: benzalkonium chloride citric acid monohydrate hydrochloric acid polyvinyl alcohol purified water sodium chloride sodium citrate dihydrate sodium hydroxide - alphagan® eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 1.5 mg/ml;   - eye drops, solution - 1.5 mg/ml - active: brimonidine tartrate 1.5 mg/ml   excipient: boric acid calcium chloride dihydrate carmellose sodium hydrochloric acid magnesium chloride hexahydrate potassium chloride purified water sodium borate pentahydrate sodium chloride sodium chlorite as purite sodium hydroxide - alphagan® p 1.5 eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 80 mg/ml - oral solution - 80 mg/ml - active: ritonavir 80 mg/ml excipient: caramel citric acid ethanol peppermint oil polyoxyl 35 castor oil propylene glycol purified water saccharin sodium sunset yellow fcf - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 20mg/0.4ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate sodium hydroxide water for injection - humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years of age and older. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate dimeticone mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate dimeticone mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 10 mg/0.2 ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate sodium hydroxide water for injection - humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years of age and older. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

abbvie limited - levobupivacaine hydrochloride - solution for injection/infusion - 2.5 milligram(s)/millilitre - amides; levobupivacaine